MYOV - Myovant Sciences: A Promising Investment Opportunity In 2020
Today, we will study why Myovant Sciences (MYOV) is a promising pick for 2020.
Company overview
Myovant Sciences is close to transforming from a clinical-stage biopharmaceutical company to a commercial organization. The company is focused on evaluating its lead asset, Relugolix in combination therapy for two women’s health conditions with significant unmet demand - uterine fibroids and endometriosis. The company is also studying Relugolix as a monotherapy for advanced prostate cancer patients. Finally, Myovant Sciences is evaluating kisspeptin agonist, MVT-602, for treating female infertility as a part of assisted reproduction.